Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731570 | 0.95 | LMNA (0.53) | MAPTLMNAALDH1A1ABCB1ALK | |
| SCHEMBL15862951 | 0.90 | LMNA (0.54) | MAPTLMNAALDH1A1ABCB1ALK | |
| SCHEMBL30497506 | 0.90 | CYP3A4 (0.47) | MAPTLMNAALDH1A1ABCB1ALK | |
| SCHEMBL1448323 | 0.90 | GPR119 (0.64) | MAPTLMNAALDH1A1GPR119 | |
| SCHEMBL17411226 | 0.90 | CYP3A4 (0.47) | MAPTLMNAALDH1A1ABCB1ALK | |
| SCHEMBL14406656 | 0.89 | EGFR (0.52) | MAPTLMNAALDH1A1ALKGPR119 | |
| SCHEMBL21133577 | 0.89 | EGFR (0.52) | MAPTLMNAALDH1A1ABCB1ALK | |
| SCHEMBL29803089 | 0.89 | EGFR (0.52) | MAPTLMNAALDH1A1ALKGPR119 | |
| SCHEMBL29788218 | 0.89 | EGFR (0.52) | MAPTLMNAALDH1A1ABCB1ALK | |
| SCHEMBL29060016 | 0.88 | EGFR (0.51) | MAPTLMNAALDH1A1ABCB1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2020-09-03 | — | — | US | claimed |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-10-08 | — | — | US | claimed |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3508204-B1 | QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER | NEUPHARMA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2025-08-19 | — | — | US | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250154134-A1 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2012061299-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061299-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2440559-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | MAPT 3204/4885LMNA 3349/4885ALDH1A1 2836/4885 |
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | ALK, IGF1R, PDGFRB | MAPT 1393/4885LMNA 2569/4885ALDH1A1 855/4885 |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | MAPT 2615/4885LMNA 4831/4885ALDH1A1 3638/4885 |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | ABCG2, CYP3A5, CYP3A43 | MAPT 1926/4885LMNA 1530/4885ALDH1A1 261/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAPT 3202/4885LMNA 1977/4885ALDH1A1 3691/4885 |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | ALK, MYC, ALKBH3 | MAPT 4564/4885LMNA 3426/4885ALDH1A1 1743/4885 |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | MAPT 1926/4885LMNA 1530/4885ALDH1A1 261/4885 |
| US-20250154134-A1 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | PTK2, PAK1, FYN | MAPT 1697/4885LMNA 3102/4885ALDH1A1 1905/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | MAPT 1903/4885LMNA 3051/4885ALDH1A1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.